Veena S. John

Veena S. John

Hematology Oncology | Oncology

450 Lakeville Road
Entrance B
Lake Success, NY 11042

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Journal: Nature communications

Published: November 05, 2025

Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial.

Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trial.

Journal: BMJ open

Published: June 05, 2025

Hepatic Yolk Sac Tumor: A Systematic Review of Presentation, Diagnosis, and Treatment.

Hepatic Yolk Sac Tumor: A Systematic Review of Presentation, Diagnosis, and Treatment.

Journal: Journal of gastrointestinal cancer

Published: May 25, 2025

Toxicity and efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer: a real-world retrospective analysis.

Toxicity and efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer: a real-world retrospective analysis.

Journal: Frontiers in oncology

Published: May 02, 2025

Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic review.

Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic review.

Journal: Gynecologic oncology reports

Published: February 18, 2025

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 20, 2024

Hemolytic Anemia Secondary to Rasburicase Treatment in the Setting of Glucose-6-Phosphate-Dehydrogenase Deficiency: A Case Report.

Hemolytic Anemia Secondary to Rasburicase Treatment in the Setting of Glucose-6-Phosphate-Dehydrogenase Deficiency: A Case Report.

Journal: Cureus

Published: October 16, 2024

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

Journal: Nature medicine

Published: September 23, 2024

Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk.

Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 20, 2024

Hemolytic Anemia and Pancytopenia Secondary to Vitamin B12 Deficiency: Evaluation and Clinical Significance.

Hemolytic Anemia and Pancytopenia Secondary to Vitamin B12 Deficiency: Evaluation and Clinical Significance.

Journal: Cureus

Published: March 29, 2024

Hydrogen peroxide bladder irrigation: A simple, safe and effective management option for clot retention.

Hydrogen peroxide bladder irrigation: A simple, safe and effective management option for clot retention.

Journal: Urology case reports

Published: September 14, 2023

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 04, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026